AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01628978 — intervention group
Intervention type: OTHER
Intervention: determination by auscultation
Description: determination of depth of endotracheal tube placement by auscultation
Study NCT01628978 — intervention group
Intervention type: OTHER
Intervention: determination by ultrasound
Description: determination of depth of endotracheal tube placement by ultrasound
Study NCT03210246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY 1002670)
Description: Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
Study NCT03210246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vilaprisan Placebo
Description: Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
Study NCT03210246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microgynon
Description: Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
Study NCT03210246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon
Description: Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
Study NCT03210246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microgynon Placebo
Description: For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
Study NCT03043209 — intervention group
Intervention type: GENETIC
Intervention: Genomic sequencing
Description: Genomic sequencing of DNA in Blood sample and myectomy tissue
Study NCT02033681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-per-mil Tumescent Solution Injection
Description: One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger.
Study NCT03210246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon Placebo
Description: For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
Study NCT03815942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-MVA 5T4 vaccine
Description: ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units
Study NCT03815942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Infusion [Opdivo]
Description: Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
Study NCT03750708 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ara® KOLIBREE tooth brush
Description: Use of the Ara® KOLIBREE tooth brush by the child one month before alveolar bone graft up to the time of surgery.~The Ara® KOLIBREE tooth brush saves brush tracking data.
Study NCT03734276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity activity
Description: Cyclo-ergometer session in high intensity setting
Study NCT01646853 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Megavoltage photon beam
Description: initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
Study NCT01646853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin-fluorouracil chemotherapy
Description: cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
Study NCT01565811 — intervention group
Intervention type: PROCEDURE
Intervention: perihepatic lymphadenectomy
Description: Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
Study NCT03734276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control arm
Description: Usual care
Study NCT03212924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
Study NCT03212924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of speech comprehension in quiet
Description: Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
Study NCT03212924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of speech comprehension in noise
Description: Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
Study NCT03212924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOCA
Description: The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
Study NCT03212924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: auto evaluation of listening effort in quiet
Description: The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
Study NCT03212924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: auto evaluation of listening effort in noise
Description: The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
Study NCT04453371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Description: In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.
Study NCT04453371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer solution
Description: In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.
Study NCT05236049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SclerFIX
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in support of intraocular implant.
Study NCT03037775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline
Description: measurement of baseline hemodynamic parameters
Study NCT03037775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: e-cigarette without nicotine
Description: measurement hemodynamic parameters during smoking e-cigarette without nicotine
Study NCT03037775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: e-cigarette with nicotine
Description: measurement hemodynamic parameters smoking e-cigarette with nicotine
Study NCT03037775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: traditional cigarette
Description: measurement hemodynamic parameters smoking traditional cigarette
Study NCT01696084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
Study NCT01696084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7+3 (cytarabine and daunorubicin)
Description: First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.
Study NCT03543475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arabin pessary
Description: arabin pessary: silicon device
Study NCT03543475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: no pessary
Description: control group
Study NCT02099578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25 g of Freeze-dried Strawberry Powder
Description: Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
Study NCT02099578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50 g of Freeze-dried Strawberry Powder
Description: Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
Study NCT02099578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Powder
Description: Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
Study NCT02099578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
Study NCT03811028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOBI003
Description: weekly i.v. infusion
Study NCT01748084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
Study NCT01748084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl)
Description: Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
Study NCT04342156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 milligram (mg) Tab
Description: Oral tablet of Hydroxychloroquine sulfate
Study NCT04342156 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine Sulfate 200 milligram (mg) Tab
Description: Oral tablet of Hydroxychloroquine sulfate
Study NCT02033681 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution is injected into the tissue as a placebo control.
Study NCT02423525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study NCT02429804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced MRI
Study NCT02429804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT02429804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Sodium Fluoride
Description: Given IV
Study NCT02429804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study NCT02429804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study NCT04059081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles.
Study NCT00578851 — intervention group
Intervention type: DEVICE
Intervention: C2a - Taper™ Acetabular System
Description: The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
Study NCT01388179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
Study NCT01388179 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
Study NCT02458677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX003
Study NCT04894851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants in the current study will receive contingencies for improvement in clutter, as measured by a trained, independent in-home rater. Ratings will be completed by after study consent, and once every month thereafter, being conducted at weeks 0, 4, 8, 12, and 16 of treatment. Participants will be reimbursed for each new 1-point reduction in CIR score, a set dollar amount per month for each CIR point reduction they maintain from baseline. Therefore, a perfectly performing patient would earn reimbursement (A CIR reduction of 8 points made in the first month and maintained throughout treatment. If a CIR score is higher than the prior month, the reinforcement schedule will reset to zero.
Study NCT02576548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product
Study NCT04014699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified 2.2mm microincision
Description: enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
Study NCT04014699 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional 2.2mm microincision
Description: conventional 2.2mm coaxial microincision phacoemulsification
Study NCT03211819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement
Description: A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement.
Study NCT03211819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement
Description: A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement.
Study NCT01683136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)
Description: on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks
Study NCT01683136 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)
Description: on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks
Study NCT03584048 — intervention group
Intervention type: OTHER
Intervention: Alert to provider
Description: Providers receive alerts of sub-optimal patient attendance using 4 rules.
Study NCT03134391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant spray, EMLA
Description: Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
Study NCT03375086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX3330
Description: APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
Study NCT00682929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Cannabis
Description: Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
Study NCT00682929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral THC
Description: Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
Study NCT00682929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo
Description: Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
Study NCT00682929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
Study NCT00682929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled placebo
Description: Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
Study NCT00682929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
Study NCT02458677 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02382653 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral perixicam
Description: Oral adminstration of buccal perixicam
Study NCT05521971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifaceted pharmacist-led intervention
Description: * Educational sessions were provided to the physicians and nursing staff.~* Discontinuation regimens were developed. Prescribers were free to choose whether or not to actually use them. The regimens were derived from the regimen used by Petrovic et al. and encouraged a switch from any benzodiazepine to lorazepam 1 mg OD for one week followed by drug stop. Z-drugs were switched to zolpidem 5 mg OD for one week followed by drug stop. If deemed necessary, a pro re nata regimen of lorazepam 1 mg or zolpidem 5 mg for one additional week was prescribed respectively. The discontinuation regimens were incorporated into the hospital's electronic prescribing system. Furthermore, a clinical decision support system provided additional support.~* Patient education sessions were provided upon enrolment and at discharge. Specific patient leaflets were used to facilitate patient education.~* The patient's primary care physician and, if applicable, the nursing home were informed by phone.
Study NCT05521971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care group
Description: all patients received comprehensive geriatric care without any systematic clinical pharmacist involvement regarding deprescribing of hypnotics. Treating physicians were not actively informed on the patient's participation in this particular study.
Study NCT00607126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: locomotor training using body weight support on a treadmill